NCT02405858 - A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 10, 2015

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions

Metastatic Castration-Resistant Prostate Cancer

Interventions

DRUG

Abiraterone Acetate

Abiraterone acetate 1000 milligram (mg) (four 250 mg tablets) orally once daily up to Cycle 26.

DRUG

Prednisolone

Oral prednisolone 5 mg will be concomitantly administered twice a day (10 mg/day) up to Cycle 26.

Trial Locations (14)

Asahi

Higashi-Ibaraki

Kanazawa

Kobe

Koshigaya

Kumamoto

Narashino

Okayama

Sagamihara

Sakura

Shinjuku-Ku

Sunto

Yokohama

Yokosuka